{"qas": [{"question": "Who put out a report in 2012?", "id": "571acf6232177014007e9f1c", "answers": [{"text": "President's Council of Advisors on Science and Technology", "answer_start": 272}], "is_impossible": false}, {"question": "What has been argued restricted innovation?", "id": "571acf6232177014007e9f1d", "answers": [{"text": "excessive regulation", "answer_start": 24}], "is_impossible": false}, {"question": "What was a recommendations brought about from the report?", "id": "571acf6232177014007e9f1e", "answers": [{"text": "expanding the FDA's use of accelerated approval processes", "answer_start": 430}], "is_impossible": false}, {"question": "What is one thing excessive regulations causes?", "id": "571acf6232177014007e9f1f", "answers": [{"text": "therapeutic innovation", "answer_start": 56}], "is_impossible": false}, {"question": "What can be used to evaluate new approval processes?", "id": "571acf6232177014007e9f20", "answers": [{"text": "pilot projects", "answer_start": 610}], "is_impossible": false}, {"question": "What is excessive drug regulation said to suppress?", "id": "571d3d015efbb31900334eda", "answers": [{"text": "therapeutic innovation", "answer_start": 56}], "is_impossible": false}, {"question": "In what year was a report made to reduce the burdens of drug development?", "id": "571d3d015efbb31900334edb", "answers": [{"text": "2012", "answer_start": 253}], "is_impossible": false}, {"question": "What was argued to be holding back new knowledge for treating diseases?", "id": "571d3d015efbb31900334edc", "answers": [{"text": "current cost of regulator-required clinical trials", "answer_start": 93}], "is_impossible": false}, {"plausible_answers": [{"text": "President's Council of Advisors on Science and Technology", "answer_start": 272}], "question": "Who put out a report in 2011?", "id": "5ad3adf5604f3c001a3fec29", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "excessive regulation", "answer_start": 24}], "question": "What has been argued restricted population?", "id": "5ad3adf5604f3c001a3fec2a", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "expanding the FDA's use of accelerated approval processes", "answer_start": 430}], "question": "What was a recommendation brought about from human disease?", "id": "5ad3adf5604f3c001a3fec2b", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "therapeutic innovation", "answer_start": 56}], "question": "What is one thing excessive development causes?", "id": "5ad3adf5604f3c001a3fec2c", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "pilot projects", "answer_start": 610}], "question": "What can be used to evaluate new human diseases?", "id": "5ad3adf5604f3c001a3fec2d", "answers": [], "is_impossible": true}], "context": "Others have argued that <a1_0><b9_0>excessive regulation<b9_0/><a1_0/> suppresses <a3_0><a5_0><b11_0>therapeutic innovation<b11_0/><a5_0/><a3_0/>, and that the <a7_0>current cost of regulator-required clinical trials<a7_0/> prevents the full exploitation of new genetic and biological knowledge for the treatment of human disease. A <a6_0>2012<a6_0/> report by the <a0_0><b8_0>President's Council of Advisors on Science and Technology<b8_0/><a0_0/> made several key recommendations to reduce regulatory burdens to new drug development, including 1) <a2_0><b10_0>expanding the FDA's use of accelerated approval processes<b10_0/><a2_0/>, 2) creating an expedited approval pathway for drugs intended for use in narrowly defined populations, and 3) undertaking <a4_0><b12_0>pilot projects<b12_0/><a4_0/> designed to evaluate the feasibility of a new, adaptive drug approval process."}